Logo

Roche's Elecsys GALAD scores Receive the US FDA's Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma

Share this

Roche's Elecsys GALAD scores Receive the US FDA's Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma

Shots:

  • The GALAD score combines gender and age with the biomarker results of the Elecsys AFP- AFP-L3 and PIVKA-II and is intended to aid diagnosis of early-stage HCC
  • The Elecsys GALAD will be the first GALAD score with regulatory approval to be used as IVD targeting the improvement in diagnostic workflows in the management of chronic liver disease
  • The Elecsys GALAD score in combination with blood-based biomarkers support clinicians by providing them accurate and timely information to make earlier interventions- thus improves patient’s outcomes and reduces the mortality rate in patients with HCC

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions